Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/7910
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorVILAR, Lucio-
dc.contributor.authorFLESERIU, Maria-
dc.contributor.authorBRONSTEIN, Marcello D.-
dc.date.accessioned2014-09-30T15:12:21Z-
dc.date.available2014-09-30T15:12:21Z-
dc.date.issued2014-
dc.identifier.citationARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, v.58, n.1, p.9-22, 2014-
dc.identifier.issn0004-2730-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/7910-
dc.description.abstractThe definition of the etiology of hyperprolactinemia often represents a great challenge and an accurate diagnosis is paramount before treatment. Although prolactin levels > 200-250 ng/mL are highly suggestive of prolactinomas, they can occasionally be found in other conditions. Moreover, as much as 25% of patients with microprolactinomas may present prolactin levels < 100 ng/mL, which are found in most patients with pseudoprolactinomas, drug-induced hyperprolactinemia, or systemic diseases. On the other hand, some conditions may lead to falsely low PRL levels, particularly the so-called hook effect, that is an assay artifact caused by an extremely high level of PRL, and can be confirmed by repeating assay after a 1:100 serum sample dilution. The hook effect must be considered in all patients with large pituitary adenomas and PRL levels within the normal range or only modestly elevated (e.g., < 200 ng/mL). An overlooked hook effect may lead to incorrect diagnosis and unnecessary surgical intervention in patients with prolactinomas. Another important challenge is macroprolactinemia, a common finding that needs to be identified, as it usually requires no treatment. Although most macroprolactinemic patients are asymptomatic, many of them may present galactorrhea or menstrual disorders, as well as neuroradiological abnormalities, due to the concomitance of other diseases. Finally, physicians should be aware that pituitary incidentalomas are found in at least 10% of adult population.-
dc.language.isoeng-
dc.publisherSBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA-
dc.relation.ispartofArquivos Brasileiros de Endocrinologia e Metabologia-
dc.rightsopenAccess-
dc.subjectHyperprolactinemia-
dc.subjectdiagnostic pitfalls-
dc.subjecthook effect-
dc.subjectmacroprolactinemia-
dc.subjectpituitary incidentalomas-
dc.subject.otherantipsychotic-induced hyperprolactinemia-
dc.subject.otherserum prolactin levels-
dc.subject.otherectopic hyperprolactinemia-
dc.subject.otherdifferential-diagnosis-
dc.subject.otherdisconnection hyperprolactinemia-
dc.subject.otherradiological features-
dc.subject.otherclinical-practice-
dc.subject.otherpituitary-tumors-
dc.subject.othermacroprolactinemia-
dc.subject.othermanagement-
dc.titleChallenges and pitfalls in the diagnosis of hyperprolactinemia-
dc.title.alternativeDesafios e armadilhas no diagnóstico da hiperprolactinemia-
dc.typearticle-
dc.rights.holderCopyright SBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA-
dc.identifier.doi10.1590/0004-2730000003002-
dc.identifier.pmid24728159-
dc.subject.wosEndocrinology & Metabolism-
dc.type.categoryreview-
dc.type.versionpublishedVersion-
hcfmusp.author.externalVILAR, Lucio:Univ Fed Pernambuco UFPE, Hosp Clin, Div Endocrinol, Recife, PE, Brazil-
hcfmusp.author.externalFLESERIU, Maria:Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Northwest Pituitary Ctr, Portland, OR 97201 USA-
hcfmusp.description.beginpage9-
hcfmusp.description.endpage22-
hcfmusp.description.issue1-
hcfmusp.description.volume58-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000336783000002-
hcfmusp.origem.id2-s2.0-84897421437-
hcfmusp.origem.idSCIELO:S0004-27302014000100009-
hcfmusp.publisher.cityRIO DE JANEIRO, RJ-
hcfmusp.publisher.countryBRAZIL-
hcfmusp.relation.referenceABRAM M, 1992, ANN ENDOCRINOL-PARIS, V53, P215-
hcfmusp.relation.referenceAlbuquerque FC, 1998, J NEUROSURG, V89, P1043, DOI 10.3171/jns.1998.89.6.1043-
hcfmusp.relation.referenceArbaiza D, 1999, MED PEDIATR ONCOL, V32, P311, DOI 10.1002/(SICI)1096-911X(199904)32:4<311::AID-MPO15>3.0.CO;2-G-
hcfmusp.relation.referenceATCHISON J A, 1989, Journal of the American Medical Association, V262, P3175, DOI 10.1001/jama.262.22.3175-
hcfmusp.relation.referenceBahuleyan B, 2009, J CLIN NEUROSCI, V16, P1421, DOI 10.1016/j.jocn.2009.03.024-
hcfmusp.relation.referenceBhatavdekar JM, 2001, DIS COLON RECTUM, V44, P119, DOI 10.1007/BF02234833-
hcfmusp.relation.referenceBiller BMK, 1999, J REPROD MED, V44, P1075-
hcfmusp.relation.referenceBronstein MD., 2010, ENDOCRINOLOGY, P333-
hcfmusp.relation.referenceBronstein MD, 2012, ENDOCRINE, V41, P169, DOI 10.1007/s12020-012-9608-0-
hcfmusp.relation.referenceBUVAT J, 1985, HORM RES, V22, P196, DOI 10.1159/000180094-
hcfmusp.relation.referenceCAVACO B, 1995, J CLIN ENDOCR METAB, V80, P2342, DOI 10.1210/jc.80.8.2342-
hcfmusp.relation.referenceDe Bellis A, 2007, ANN NY ACAD SCI, V1107, P129, DOI 10.1196/annals.1381.014-
hcfmusp.relation.referenceDemirtas Y, 2004, DERMATOL SURG, V30, P1184, DOI 10.1111/j.1524-4725.2004.30354.x-
hcfmusp.relation.referenceDonadio F, 2007, EUR J CLIN INVEST, V37, P552, DOI 10.1111/j.1365-2362.2007.01823.x-
hcfmusp.relation.referenceDuarte FHG, 2008, ARQ BRAS ENDOCRINOL, V52, P1189, DOI 10.1590/S0004-27302008000700017-
hcfmusp.relation.referenceElenkova A, 2013, EXP CLIN ENDOCR DIAB, V121, P201, DOI 10.1055/s-0032-1333232-
hcfmusp.relation.referenceElms AF, 2012, PITUITARY, V15, P552, DOI 10.1007/s11102-011-0366-4-
hcfmusp.relation.referenceFALASCHI P, 1980, OBSTET GYNECOL, V55, P579-
hcfmusp.relation.referenceFilho Roberpaulo Barboza, 2007, Gynecol Endocrinol, V23, P267, DOI 10.1080/09513590701297708-
hcfmusp.relation.referenceFleseriu M, 2006, J NEURO-ONCOL, V79, P41, DOI 10.1007/s11060-005-9108-7-
hcfmusp.relation.referenceFreda PU, 1999, ENDOCRIN METAB CLIN, V28, P81, DOI 10.1016/S0889-8529(05)70058-X-
hcfmusp.relation.referenceFreitas MC, 2013, ENDOCRINOLOGIA CLIN, P297-
hcfmusp.relation.referenceFrieze Todd W, 2002, Endocr Pract, V8, P296-
hcfmusp.relation.referenceGibney J, 2005, J CLIN ENDOCR METAB, V90, P3927, DOI 10.1210/jc.2004-2234-
hcfmusp.relation.referenceGillam MP, 2011, PITUITARY, 3RD EDITION, P119, DOI 10.1016/B978-0-12-380926-1.10005-7-
hcfmusp.relation.referenceGlezer A, 2008, ENDOCRIN METAB CLIN, V37, P195, DOI 10.1016/j.ecl.2007.10.003-
hcfmusp.relation.referenceGlezer A, 2002, CLIN ENDOCRINOL, V57, P135, DOI 10.1046/j.1365-2265.2002.01567.x-
hcfmusp.relation.referenceGlezer A, 2012, J CLIN ENDOCR METAB, V97, P2211, DOI 10.1210/jc.2011-2976-
hcfmusp.relation.referenceGlezer A, 2006, J CLIN ENDOCR METAB, V91, P1048, DOI 10.1210/jc.2005-1831-
hcfmusp.relation.referenceGuay AT, 1996, J CLIN ENDOCR METAB, V81, P2512, DOI 10.1210/jc.81.7.2512-
hcfmusp.relation.referenceHayashida SA, 2013, CLIN ENDOCRINOL OXF-
hcfmusp.relation.referenceHekimsoy Z, 2010, ENDOCR J, V57, P1011, DOI 10.1507/endocrj.K10E-215-
hcfmusp.relation.referenceHOFFMAN WH, 1987, CANCER, V60, P2690, DOI 10.1002/1097-0142(19871201)60:11<2690::AID-CNCR2820601119>3.0.CO;2-J-
hcfmusp.relation.referenceHONBO KS, 1978, AM J MED, V64, P782, DOI 10.1016/0002-9343(78)90517-X-
hcfmusp.relation.referenceHOU SH, 1985, AM J KIDNEY DIS, V6, P245-
hcfmusp.relation.referenceHSU CT, 1992, GYNECOL ONCOL, V44, P166, DOI 10.1016/0090-8258(92)90033-F-
hcfmusp.relation.referenceHuang WY, 2012, AM FAM PHYSICIAN, V85, P1073-
hcfmusp.relation.referenceInder WJ, 2011, AUST NZ J PSYCHIAT, V45, P830, DOI 10.3109/00048674.2011.589044-
hcfmusp.relation.referenceIsik S, 2012, ENDOCRINE, V41, P327, DOI 10.1007/s12020-011-9576-9-
hcfmusp.relation.referenceJACKSON RD, 1985, J CLIN ENDOCR METAB, V61, P258-
hcfmusp.relation.referenceJamaluddin F A, 2013, Malays J Pathol, V35, P59-
hcfmusp.relation.referenceJohnsen E, 2008, J CLIN PSYCHOPHARM, V28, P686, DOI 10.1097/JCP.0b013e31818ba5d8-
hcfmusp.relation.referenceJOSIMOVICH JB, 1987, FERTIL STERIL, V47, P785-
hcfmusp.relation.referenceKALLENBERG GA, 1990, JAMA-J AM MED ASSOC, V263, P2472, DOI 10.1001/jama.263.18.2472-
hcfmusp.relation.referenceKamel N, 1999, ENDOCR J, V46, P505, DOI 10.1507/endocrj.46.505-
hcfmusp.relation.referenceKaravitaki N, 2006, CLIN ENDOCRINOL, V65, P524, DOI 10.1111/j.1365-2265.2006.02627.x-
hcfmusp.relation.referenceKasum M, 2012, BIOCHEM MEDICA, V22, P171-
hcfmusp.relation.referenceKLEINBERG DL, 1977, NEW ENGL J MED, V296, P589, DOI 10.1056/NEJM197703172961103-
hcfmusp.relation.referenceKorevaar T, 2012, CLIN ENDOCRINOL, V76, P602, DOI 10.1111/j.1365-2265.2011.04226.x-
hcfmusp.relation.referenceKunwar AR, 2003, ANN PHARMACOTHER, V37, P206-
hcfmusp.relation.referenceLA TORRE D., 2007, THER CLIN RISK MANAG, V3, P929-
hcfmusp.relation.referenceLu CC, 2012, KAOHSIUNG J MED SCI, V28, P94, DOI 10.1016/j.kjms.2011.10.030-
hcfmusp.relation.referenceMah PM, 2002, SEMIN REPROD MED, V20, P365, DOI 10.1055/s-2002-36709-
hcfmusp.relation.referenceMancini T, 2008, ENDOCRIN METAB CLIN, V37, P67, DOI 10.1016/j.ecl.2007.10.013-
hcfmusp.relation.referenceMcKenna TJ, 2009, CLIN ENDOCRINOL, V71, P466, DOI 10.1111/j.1365-2265.2009.03577.x-
hcfmusp.relation.referenceMelmed S, 2011, J CLIN ENDOCR METAB, V96, P273, DOI 10.1210/jc.2010-1692-
hcfmusp.relation.referenceModest GA, 2002, NEW ENGL J MED, V347, P1626, DOI 10.1056/NEJM200211143472020-
hcfmusp.relation.referenceMolitch ME, 2012, NEUROSURG CLIN N AM, V23, P543, DOI 10.1016/j.nec.2012.06.003-
hcfmusp.relation.referenceMolitch ME, 2008, PITUITARY, V11, P209, DOI 10.1007/s11102-008-0106-6-
hcfmusp.relation.referenceMolitch ME, 2001, ENDOCRIN METAB CLIN, V30, P585, DOI 10.1016/S0889-8529(05)70203-6-
hcfmusp.relation.referenceMORGAN MY, 1978, GUT, V19, P170, DOI 10.1136/gut.19.3.170-
hcfmusp.relation.referenceNaidich MJ, 1999, ENDOCRIN METAB CLIN, V28, P45, DOI 10.1016/S0889-8529(05)70057-8-
hcfmusp.relation.referenceNardoni A, 1985, Minerva Med, V76, P37-
hcfmusp.relation.referenceNotsu K, 1997, ENDOCR J, V44, P89, DOI 10.1507/endocrj.44.89-
hcfmusp.relation.referencePALMER PE, 1990, OBSTET GYNECOL, V75, P540-
hcfmusp.relation.referencePetit A, 2003, THERAPIE, V58, P159, DOI 10.2515/therapie:2003023-
hcfmusp.relation.referenceProust-Lemoine E, 2008, ANN ENDOCRINOL-PARIS, V69, P240, DOI 10.1016/j.ando.2008.01.004-
hcfmusp.relation.referenceRobin G, 2011, GYNECOL OBSTET FERTI, V39, P141, DOI 10.1016/j.gyobfe.2010.11.002-
hcfmusp.relation.referenceShimatsu A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/167132-
hcfmusp.relation.referenceSimsir IY, 2012, GYNECOL ENDOCRINOL, V28, P148, DOI 10.3109/09513590.2011.589923-
hcfmusp.relation.referenceSINHA YN, 1995, ENDOCR REV, V16, P354, DOI 10.1210/er.16.3.354-
hcfmusp.relation.referenceSMITH MV, 1994, NEUROSURGERY, V34, P834-
hcfmusp.relation.referenceSmith TP, 2002, J CLIN ENDOCR METAB, V87, P5410, DOI 10.1210/jc.2001-011943-
hcfmusp.relation.referenceLeaes CGS, 2011, NEUROENDOCRINOL LETT, V32, P616-
hcfmusp.relation.referenceSTANISIC TH, 1986, J UROLOGY, V136, P85-
hcfmusp.relation.referenceStrachan MWJ, 2003, CLIN ENDOCRINOL, V59, P339, DOI 10.1046/j.1365-2265.2003.01852.x-
hcfmusp.relation.referenceSTRYKER TD, 1985, AM J MED, V79, P271, DOI 10.1016/0002-9343(85)90022-1-
hcfmusp.relation.referenceSUH HK, 1974, J CLIN ENDOCR METAB, V39, P928-
hcfmusp.relation.referenceSuliman AM, 2003, CLIN CHEM, V49, P1504, DOI 10.1373/49.9.1504-
hcfmusp.relation.referenceSun GEC, 2013, PITUITARY, V16, P351, DOI 10.1007/s11102-012-0431-7-
hcfmusp.relation.referenceTamer G, 2012, ENDOCRINE, V41, P138, DOI 10.1007/s12020-011-9536-4-
hcfmusp.relation.referenceTarin JJ, 2013, REPROD BIOL ENDOCRIN, V11, DOI 10.1186/1477-7827-11-39-
hcfmusp.relation.referenceTEOH SK, 1992, J STUD ALCOHOL, V53, P176-
hcfmusp.relation.referenceThirunavakkarasu K, 2013, ENDOCRINE, V44, P750, DOI 10.1007/s12020-013-9925-y-
hcfmusp.relation.referenceVallette-Kasic S, 2002, J CLIN ENDOCR METAB, V87, P581, DOI 10.1210/jc.87.2.581-
hcfmusp.relation.referenceVANCE ML, 1987, ENDOCRIN METAB CLIN, V16, P731-
hcfmusp.relation.referenceVieira JG, 1988, CLIN CHEM, V44, P1758-
hcfmusp.relation.referenceVieira JGH, 2010, ARQ BRAS ENDOCRINOL, V54, P856, DOI 10.1590/S0004-27302010000900013-
hcfmusp.relation.referenceVilar L, 2007, MINERVA ENDOCRINOL, V2, P79-
hcfmusp.relation.referenceVilar L, 2013, ENDOCRINOLOGIA CLIN, P39-
hcfmusp.relation.referenceVilar L, 2007, ARQ BRAS ENDOCRINOL, V51, P86, DOI 10.1590/S0004-27302007000100014-
hcfmusp.relation.referenceVilar Lucio, 2003, Arq Bras Endocrinol Metab, V47, P347, DOI 10.1590/S0004-27302003000400007-
hcfmusp.relation.referenceVilar Lucio, 2007, Endocr Pract, V13, P396-
hcfmusp.relation.referenceVilar Lucio, 2005, Arq Bras Endocrinol Metabol, V49, P651, DOI 10.1590/S0004-27302005000500006-
hcfmusp.relation.referenceVilar L, 2008, J ENDOCRINOL INVEST, V31, P436-
hcfmusp.relation.referenceVoicu V, 2013, EXPERT OPIN DRUG MET, V9, P955, DOI 10.1517/17425255.2013.791283-
dc.description.indexMEDLINE-
dc.identifier.eissn1677-9487-
hcfmusp.citation.scopus60-
hcfmusp.scopus.lastupdate2024-03-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/25
LIM/25 - Laboratório de Endocrinologia Celular e Molecular


Files in This Item:
File Description SizeFormat 
art_VILAR_Challenges_and_pitfalls_in_the_diagnosis_of_hyperprolactinemia_2014.PDFpublishedVersion (English)405 kBAdobe PDFThumbnail
View/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.